Statistical tests were conducted at a two-sided significance level of 0

Statistical tests were conducted at a two-sided significance level of 0.05. Patients with PID and healthy volunteers aged 12 years, residing in Japan, and with access to a smartphone were eligible. HR-QOL (primary endpoint) was assessed by the EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) and the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36). Work Raphin1 acetate productivity was assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire. Other aspects of PID and burden were assessed with a new questionnaire developed in-house. The Raphin1 acetate study is registered at the University hospital Medical Information Network clinical trials registry (UMIN000045622). Results The full interim analysis set comprised 71 patients with PID and 47 healthy volunteers. The most common International Union of Immunological Societies PID category was primary antibody deficiency (56.3% of patients). Complications were common, especially recurrent respiratory tract infections (63.4%). Most patients with PID were treated with immunoglobulin replacement therapy (73.2%); 22.4% of these patients had serum immunoglobulin levels <700 mg/dL. Among patients who did not undergo hematopoietic cell transplantation, EQ-5D-5L (n=67) and SF-36 (n=59) Physical and Mental Component Summary scores were significantly lower than in healthy volunteers (p < 0.001). WPAI absenteeism, work productivity loss, and activity impairment scores were significantly lower in 42 working patients with PID than in 37 working healthy volunteers (p < 0.05). Other results indicated that patients with PID experience substantial burdens related to medical visits, expenses, work, and daily activities. Discussion This interim analysis confirms that patients with PID in Japan have lower HR-QOL and work productivity compared with healthy individuals and experience substantial limitations and burdens in their daily lives. Keywords: 36-Item Short Form Health Survey (SF-36), activities of daily living, immunoglobulin replacement therapy, Japan, patient reported outcome measures, primary immunodeficiency diseases, quality of life, Work Productivity and Activity Impairment (WPAI) Questionnaire 1.?Introduction Primary immunodeficiency disease (PID) refers to inherited diseases caused by genetic variants of immunoregulatory proteins, resulting in impairment of the immune system (1, 2). PID is primarily characterized by increased susceptibility to infections but can also result in autoimmune diseases, autoinflammatory diseases, and malignancies (1, 2). PID ranges from mild forms that do not require ongoing treatment Raphin1 acetate to critically severe forms, such as severe combined immunodeficiency, that require immediate life-saving intervention. Immunoglobulin replacement therapy (IgRT) is the standard supportive treatment for most patients with antibody deficiencies, although more definitive options, such as allogeneic hematopoietic cell transplantation (HCT), may be suitable for some patients (3, 4). Prophylactic antibiotic and antifungal medications are also often prescribed (4). PID is considered a rare disease, occurring in 1 per 10,000 to Raphin1 acetate 1 1?per 50,000 live births, although recent evidence suggests the prevalence may be much higher (5). In Japan, PID occurs in 2.2?per 100,000 persons and is designated as an intractable disease eligible for public assistance (6). To date, nearly 500 PID disorders have been described; these Rabbit Polyclonal to VAV3 (phospho-Tyr173) disorders have been classified by the International Union of Immunological Societies (IUIS) based on phenotypic and genetic characteristics (2). In Japan, the most common IUIS categories are primary antibody deficiency (40%), congenital phagocyte dysfunction or defect (19%), and characteristic syndromes associated with immunodeficiency (16%); the most common clinical forms of PID are X-linked agammaglobulinemia (XLA; 15%), chronic granulomatosis disease (12%), and common variable immunodeficiency Raphin1 acetate (CVID; 11%) (7). People with PID often experience lower health-related quality of life (HR-QOL) and limitations on their daily activities compared with healthy individuals (8C11). Ongoing symptoms, complications, and recurrent infections, as well as physical and financial burdens related to treatment, reduce HR-QOL. In addition, daily activities, particularly those related to school and work, are often substantially limited by PID. A survey conducted by the European Federation of Pharmaceutical Industries and Associations Japan (EFPIA Japan) indicated that patients with PID in Japan experience PID-related burdens, limitations on daily activities, and frequent complications and infections despite treatment (12). Although the survey provided insights into the effects of PID on patients in Japan, it did.